Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more than two decades. It works by stopping nerve cells from sending pain signals to the brain.

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.